Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase two study of high dose blinatumomab in Richter's syndrome.

Leukemia - 1 Sept 2022

Thompson Philip A, Jiang Xianli, Banerjee Pinaki, Basar Rafet, Garg Naveen, Chen Ken, Kaplan Mecit, Nandivada Vandana, Cortes Ana Karen Nunez, Ferrajoli Alessandra, Keating Michael J, Peterson Christine B, Andreeff Michael, Rezvani Katayoun, Wierda William G

Abstract excerpt

Richter's Syndrome (RS) is an aggressive transformation of CLL, usually clonally-related diffuse large B-cell lymphoma (DLBCL), characterized by frequent TP53 mutations, intrinsic chemoresistance and poor survival. TP53-independent treatments are needed. We conducted a single center, phase 2, investigator-initiated study of high dose blinatumomab (maximum 112 mcg/d after initial, weekly dose escalation),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35941212
DOI: 10.1038/s41375-022-01649-3
PMCID: PMC9467861

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase two study of high dose blinatumomab in Richter's syndrome.PMID 35941212Read ↗

Treatment of Richter's syndrome.Semantic proximity Read ↗

Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.Semantic proximity Read ↗

Richter's syndrome: Novel and promising therapeutic alternatives.Semantic proximity Read ↗

Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel AgentsSemantic proximity Read ↗

Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndromeSemantic proximity Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.Semantic proximity Read ↗

Richter syndrome: molecular insights and clinical perspectivesSemantic proximity Read ↗

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.Semantic proximity Read ↗

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.Semantic proximity Read ↗

Richter's transformation in chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.